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CHAPTER I 
 
 
 
RATIONALE AND SPECIFIC AIMS 
 
 
 
Rationale 
 
Cancer is currently estimated to account for 22.7% of all deaths in the United States, 
making it the second most common cause of death.  In women between the ages of 40 and 
79, cancer is the leading killer.  Breast cancer is the second leading cause of cancer deaths in 
women, below lung cancer and above colon/rectal cancer.  An estimated 212,920 new cases 
of breast cancer will be diagnosed in 2006.  40,970 women are expected to die from it in 
2006.  As with most other cancers, breast cancer mortality rates have been trending 
downward, but the number of new cases is still large.  Current estimates predict that one in 
twelve women will develop breast cancer in her lifetime40. 
Campaigns touting breast cancer awareness and early detection have been 
instrumental in this downward trend.  However, improving the reliability and ease to the 
patient and physician of early detection methods will encourage more Americans to seek 
early diagnosis and prevention of cancer.  The likelihood of surviving any cancer is inversely 
proportional to the progress of that cancer upon its diagnosis and the initiation of treatment52.   
The identification of enzymes and other proteins secreted either exclusively by cancer 
cells or differentially relative to normal tissue cells is crucial to improving early detection 
methods.  The ideal cancer marker will be detectable through reliable, non-invasive methods 
such as the analysis of saliva, sweat or urine.  Barring that, minimally invasive methods such 
as blood sampling or the administration of a detection agent that could passively detect 
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malignant activity and even give location information would be a significant improvement as 
well20.   
There are few reliable cures for cancer, and any increase in effectiveness will 
likely require tailoring to the individual case based on the patient, cancer location, cancer 
stage, and other factors.  The development of quick, reliable, means of targeting specific 
types of malignant cells will be an important step to personalized cancer treatment.  
There exists a wealth of ideas on this front, many of which are currently in the conceptual 
and experimental stages.  Proof of a therapeutic approach’s effectiveness by 
experimentation is a crucial step towards clinical acceptance of the approach. 
Specific Aims 
Approximately half of the work in this thesis is dedicated to measuring production 
of matrilysin by five human cell lines isolated from benign and malignant breast and 
colon tumors.  Specific knowledge of matrilysin production capabilities will allow 
precise configuration of therapies targeting colon, breast, and other tumors that employ 
the action of the enzyme.  The methods used in this experiment can also be carried over 
to studies of other proteases, provided that sufficient detection measures are available. 
In her master’s thesis, Ashley Aston-Weiner described a method by which she 
used phage display to isolate a heptamer peptide fusion displayed on the pIII coat of M13 
that would allow the phage to enter the breast cancer cell lines MCF-7 and MCF10A and 
locate to their nuclei.  She found several sequences associated with nuclear-localized 
phage, one of which was Gln-Pro-Ser-Pro-Ser-Pro-Thr (QPSPSPT).  While she provided 
evidence of their nuclear targeting ability by amplifying the phage recovered from 
isolated nuclei, she experienced difficulty in visually verifying the process95.  The other 
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half of this thesis describes this phase of the project: the visual verification of nuclear-
targeting function of M13 bacteriophage using direct fluorochrome labeling and detection 
with nuclear staining and subsequent fluorescence microscopy. 
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CHAPTER II 
 
MANUSCRIPT 1: VISUALIZATION OF PHAGE LOCALIZATION 
 
Introduction 
 
Gene Therapy – From Theory to Laboratory 
The world of genetics sprang to the forefront of the public scientific consciousness 
during the biotechnology revolution of the 1990s.   At the helm of this explosion of 
popularity sat gene therapy, bolstered by its promise of being able to cure any ailment that 
had a genetic basis, and perhaps some that didn’t.  Kary Mullis’ discovery of the Polymerase 
Chain Reaction which allowed simple, cheap, specific, and quick mass replication of as little 
as a single strand of DNA opened up the field in 198858.   
On paper, gene therapy is so simple as to be attractive to the layperson: first, a cloned 
gene is inserted into a genetic construct using molecular “scissors,” restriction 
endonucleases.  Next, the genetic construct is similarly spliced into the genome of a virus 
that has the ability to replicate engineered out of it, or the construct is attached to or inserted 
into a carrier.  This virus or synthetic carrier acts as a vector to insert the viral genome with 
the therapeutic gene spliced in into the host cell genome or to deposit a plasmid cargo into 
the nucleus.  The host cell then expresses the newly inserted gene, replacing the defective 
gene or producing a protein that will alleviate an undesired condition70.  
However, the realities of gene therapy’s complexity were soon revealed.  Viral 
vectors are frequently immunoreactive and thus decrease the possibility for repeated 
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administrations.  The most familiar viral vector, the adenovirus, inserts a genetic construct 
that does not integrate into the host cell genome, thus causing a transient expression that is 
insufficient for replacing an undesired gene and therefore not an acceptable solution for long-
term management of a genetic ailment42.   
Ideally, gene therapy permanently resolves a monogenic disorder by supplementing 
the defective gene with a corrected gene in a sufficient number of cells to remove most or all 
of the negative effects of the disorder.  Many in the field also see potential for gene therapy 
in treating polygenic disorders, through the same method as above or by producing an 
auxiliary protein product that interacts with an undesired protein product to inactivate or 
counteract its negative effect.  Another approach, still largely in the theoretical realm, is to 
“switch” a transfected gene on or off by administration of a particular medicine, or, even 
more conveniently, by conditional expression of a particular protein product.  The eventual 
nuclear signaling that would occur as a response to the cell’s detection of the protein or 
medicine could trigger the transcription of the transfected gene.  For example, a cancer 
“vaccine” of sorts could be developed in which a large number of cells express the protein 
product of a transfected gene in response to the action of an enzyme or other protein product 
overexpressed by malignant cells18.   
The lessons and techniques learned through the many studies of gene therapy have 
resulted in its approaches being applied to animal modeling.  Animal models, especially 
those created with mice, are a huge benefit to researchers studying the immune system and 
cancer, among other things.  The ability of selective removal or conditional deactivation of a 
gene has led to many important discoveries of gene function, many of which can be assumed 
to have similar effects in their human orthologues.  Knockout mice can be created by 
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selectively breeding or cutting out (by engineering) a desired gene or genes in the embryonic 
or stem cells of a mouse.  Series of knockout mice can be used to discern the controlling 
factors and protein products involved in a particular pathway.  Much understanding of the 
human genome and disease processes has been gained from animal modeling, and the field is 
currently very active, with hundreds of papers being published annually5. 
 
Gene Therapy Modalities 
There are typically considered to be four types of viral gene therapy: adenoviruses, 
adeno-associated viruses, retroviruses, and other.  As mentioned above, a frequent problem 
with the use of viral vectors is inflammation and immunoreactivity with subsequent 
treatments.  However, when compared to the current non-viral methods, viral gene therapy 
more often results in efficient transfection of target cells.    
Adenoviruses are a group of 26 known viruses that have approximately a 35 kilobase 
double-stranded DNA genome and can accommodate inserts of up to 2 kilobases; they are 
approximately 100 nm in diameter.  Adenoviruses derive their name from their ability to 
cause mild respiratory tract infections in humans.  Typical method of entry is through the 
coxsackie-adenovirus receptor (CAR), which binds to the adenovirus coat proteins and the 
αυβ3 integrins.  The virus then enters the host cell via a clathrin coated pit.  The viral genome 
replicates independently of the host cell’s chromosomes.   Numerous studies on adenoviruses 
for gene therapy have found that serotypes 2 and 5 are the most efficient for gene therapy, 
and deletion of the E1 gene prevents virus renewal.  Adenoviruses have many significant 
advantages.  High titers are reliably attainable, the viruses can infect both dividing and non-
dividing cells, and the viruses can be covered with a co-polymer, which theoretically can 
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reduce their immunoreactivity by covering immunogenic surface proteins while still 
preserving vector function12.  
The major disadvantage of adenoviruses besides their capacity to elicit an immune 
response is that these vectors do not integrate into the host cell genome.  This coupled with 
the sometimes-dangerous immune response created by the virus’s presence makes attempted 
transfection of a therapeutic gene transient at best, and a toxic failure at worst.  Problems of 
immunogenicity and packaging limits are currently being addressed with “gutless” 
adenoviruses, which use a helper adenovirus in a tissue culture to obtain the proteins 
necessary to infect human cells without having to possess the DNA that codes for them.  
While this new technology is encouraging, it does not meet the challenges of versatile or 
long-term expression, and contamination of the gutless adenovirus titer with helper virus is 
still a problem that prevents its advancement into clinical trials17. 
Adeno-associated viruses are 
small parvoviruses which got their 
name from their discovery as a 
contaminant of adenovirus cultures.  
They are much smaller than 
adenoviruses, having a diameter 
between 18 and 26 nm and weighing 
between 5.5 and 6.2 megadaltons.  
Adeno-associated viruses posses a 
single-stranded DNA genome of approximately 4.7 kilobases (this genome must be cut down 
to 4.4 kilobases for gene therapy purposes) and are not pathogenic.  In order to replicate, they 
Figure 1:  Specific transfection of retinal ganglion cells 
with a green fluorescent protein gene using an adeno-
associated viral vector.  Note the clear path of the axons1.
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require the host cell to be infected by another virus, usually an adenovirus or herpes-family 
virus.  However, in the absence of these “helper viruses,” adeno-associated viruses are in a 
latent phase, where they integrate their genome into the host cell’s genome.  Once inside the 
host cell, the protein portions of the virus are quickly broken down.  It is this latent phase that 
makes adeno-associated viruses so attractive for gene therapy77.   
By integrating their genome with that of the host cell without undergoing replication, 
the virus can avoid eliciting an immune response while sustaining long-term expression.  
Adeno-associated viruses infect both dividing and non-dividing cells, making them 
especially attractive for infecting the retina.  Furthermore, the virus enters the cell by binding 
to heparin sulfate proteoglycans, which are exposed on a broad range of cells.  While adeno-
associated viruses are currently the most successfully employed viral vectors for gene 
therapy, they cannot accommodate large inserts because of their 4.4 kilobase limit.  Of the 
known adeno-associated virus serotypes, number 5 is currently considered to be the safest 
and most efficient88.   
Retroviruses are a family of viruses with an enveloped single-stranded RNA genome.  
Important genera include oncovirinae, lentivirinae, and spumavirinae67.  Retroviruses get 
their name from the fact that they must use the enzyme reverse transcriptase to transcribe 
their RNA genome into a DNA genome inside the host cell.  Retroviruses currently possess 
several disadvantages that currently make them unattractive for use as gene therapy vectors, 
but they have some interesting properties that could be exploited.  Retroviruses require 
breakdown of the nuclear envelope in order to integrate their genome into that of the host 
cell, which means they only infect dividing cells.  The probability of reversion of an 
engineered retrovirus to its wild-type form by interaction with “helper cells” is a significant 
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risk when using these vectors.  However, retroviruses can obtain high titers and can 
accommodate up to 7.5 kilobases of foreign DNA.  An interesting feature of retroviruses is 
that they can somehow absorb other viral proteins, potentially giving engineers the ability to 
introduce novel or known targeting proteins into the retrovirus coat that would allow 
targeting of specific cell types, a process known as “pseudotyping.” 54 
Lentiviruses are a genus of retrovirus which have added advantages as well as added 
disadvantages.  Unlike typical retroviruses, lentiviruses can infect non-dividing cells.  Long 
term expression of transfected genes delivered via lentiviruses has been shown17.  However, 
the only lentivirus currently being studied for gene therapy is a highly modified form of the 
human immunodeficiency virus (HIV).  Because of the aforementioned risk of wild-type 
reversion by recombination, there is always some risk in using modified HIV as a vector in 
humans.  Thus, there are currently no clinical trials in progress using this vector, but its 
ability to efficiently transfect human cells, including corneal epithelial cells, has been shown 
in animal models.  Therefore, lentiviruses could become useful to humans in the future or in 
gene therapy of animals.   
Many examples of non-viral gene therapy have been conceived over the years, a great 
deal of which have been abandoned, but there remain several that are still heavily studied5.  
These multiple dead-ends that researchers encountered with viral delivery methods led many 
to consider non-viral methods, ranging from the “gene gun7” to the biomimetic liposome-
DNA complex4 to simply “naked DNA.43”  A major issue with all non-viral methods is that 
they employ plasmids rather than a genomic integration approach.  A major reason for this is 
the inability to target these vectors to the nucleus in a non-cytotoxic manner.  The main 
limiting factor in non-viral gene therapy is the ability to get DNA, be it in plasmid or loose-
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strand form, to the nucleus of a cell once the non-viral transport construct has entered the 
cytoplasm.   
Non-viral vectors can be divided into two broad categories: physical and chemical.  
Most physical methods include mechanical, electrical, and surgical modes of transduction.  
The aforementioned “gene gun” would be an example of a mechanical method – using force 
to push a plasmid attached to a gold nanoparticle through the cell membrane.  While the 
DNA-containing construct often enters the cell successfully, nuclear damage can occur and 
the efficiency and specificity are poor.  Electroporation uses a quick jolt of electricity to 
reversibly permeabilize the cell membrane.  This can be done reliably without inflammation 
or significant damage occurring, but since the DNA is in the form of a plasmid, any 
expression will be transient.  A promising surgical method is to use carbon nanotubes coated 
with a protective carbohydrate as a syringe to safely pierce the cell membrane and deliver a 
plasmid to the cell nucleus.  Carbon nanotubes can also be functionalized with a positively 
charged ion such as ammonium that will allow DNA to attach.  These nontoxic nanotube-
DNA complexes can then passively enter the cell26.   
The chemical category of non-viral vectors is a somewhat abstract definition, as most 
physical methods require chemical ligations to achieve their ends.  Thus, chemical methods 
can be used either alone or to supplement other gene therapy modalities.  Fort example, high 
salt solutions or environments containing polycations can improve transduction.  This is 
currently only feasible for ex vivo or in vitro transfections.  The major chemical method 
currently being pursued is the development of liposomes.  At their simplest, these constructs 
are simply lipid bilayer spheres that contain DNA.  However, their use in gene therapy can be 
enhanced by using cationic lipids and functionalizing the liposomes with targeting proteins 
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such as viral peptides or antibody variable regions4.   While some nonviral vectors are 
promising, others are obvious dead ends.  The major disadvantage with the current crop of 
non-viral vectors is that they all employ plasmids, which obviates their potential for causing 
long-term expression of the therapeutic gene.  With all of the non-viral methods studied so 
far, in vivo transfection has not been performed with acceptable efficiency or permanent 
expression. 
While gene therapy has mostly vanished from mass market periodicals and been 
replaced by proteomics at the top of the syllabi of introductory biotechnology courses, it 
remains a heavily researched field, albeit one with less frequent dramatic breakthroughs.  The 
hunt for the “ideal vector” is still in progress, and many believe its discovery, should it come, 
will be the “second wind” for the field. This ideal vector will be safe (non-immunogenic with 
a low risk of insertional mutagenesis), relatively cheap to mass-produce, be easily 
customizable to target a wide variety of cells in a significant majority of patients, possess 
long-term expression and stability, and have a high capacity for therapeutic DNA, allowing it 
to fix genes of any biologically relevant length. Whether or not gene therapy will one day be 
the answer to the majority of humanity’s ailments is an answer that is still waiting in the 
wings, but its potential still shines bright in the eyes of many scientists and engineers12. 
 
M13 Bacteriophage 
M13 is one of a group of filamentous bacteriophages, so named because of their 
proportions.  A single typical M13 virion is approximately 6.5 nm in diameter and is 930 
nm long, giving it the proportions of a “four foot long pencil.”  M13 has several coat 
proteins; the ones of interest to the project are pVIII and pIII.  The M13 virion has 
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approximately 2,700 copies of the pVIII protein on its surface, but only 5 copies of the 
pIII coat protein, all of which are concentrated at one end of the virion.  Despite their 
reduced number, the pIII coat proteins are responsible for binding to the F-pilus of E. 
Coli37.   
Upon phage binding, the pilus retracts, pulling the phage towards the bacterium.  
The N1 domain of the pIII phage protein interacts with the TolA protein on the bacterium 
membrane, facilitating phage DNA entry.  Once inside the bacterium, the single-stranded 
DNA of the phage is transcribed to its double-stranded form, and select proteins from the 
phage amplify this transcript, and more phages are produced.  M13 is a non-lytic phage—
it does not kill the host bacterium.  However, 
the host bacterium’s division rate is reduced 
by approximately one-half69.   
While bacteriophages only reproduce 
in bacteria, they have been shown to enter 
eukaryotic cells.  A study by Giovine et al. 
goes into detail on the method of cell entry by 
phages27.  In their experiment, they engineered 
M13 bacteriophages to display an adenovirus 
peptide that facilitated cellular entry.  The 
paper contained several excellent electron micrographs depicting phage entry into 
eukaryotic cells, and the pictures indicate that it is a combination of membrane protein 
interaction and pinocytosis (Figure 2). 
 
Figure 2: Electron micrograph of M13 
bacteriophages (black arrow) entering a HeLa 
cell27. 
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Phage Display 
Phage display is an indirect method of genetic engineering in which random 
peptides displayed on the coat proteins of bacteriophage are detected and classified by a 
selection or screen.  Phages of interest are amplified in E. coli, and phage DNA is 
sequenced and analyzed to discover the sequence of the peptide of interest.  Phage 
display is commonly employed as a low-cost method to discover novel antibody binding 
motifs, but more elaborate uses for it have been discovered as well.  For example, 
insertion of random sequences followed by a linker domain can be used to detect protease 
substrates.  Phages displaying certain ligands have been shown to act as seeds in the 
formation of silver nanocrystals37.   
 
Nuclear Entry 
Separating the nucleus from cytoplasm in non-dividing cells is the nuclear 
envelope, consisting of a phospholipid bilayer and various proteins, including pores 
formed by nuclear pore complexes.  These pores regulate passage of cytoplasmic objects 
through the nuclear envelope.  Passage through the nuclear pore complex can be either a 
passive or an active process.  Besides ions and small compounds, compact proteins up to 
approximately 60 kDa can diffuse through the complex.  Large proteins and protein-
nucleic acid complexes are selectively transported into and out of the nucleus, and must 
interact with the transporter proteins of the nuclear pore complex46.   
A “nuclear localization sequence” is required in order for a protein to be 
transported through the complex.  The first nuclear localization sequence to be 
characterized was in the large-T antigen of the simian virus 40.  A seven-peptide, highly-
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basic, highly hydrophilic region, PKKKRKV, was identified as the nuclear localization 
sequence for the virus.  Other nuclear localization sequences have been identified since 
then, and some have different chemical properties, such as high hydrophobicity29. 
Four required proteins have been identified in the active nuclear import process: 
Ran, NTF2, and the importins α and β.  Briefly, the importins form a complex, with the α 
subunit binding to the nuclear localization sequence of a cargo protein, and the β subunit 
interacting with the FG-nucleoporins of the nuclear pore complex.  The FG nucleoporins 
are so named because of their hydrophobic regions of repeated phenyalanine (F) and 
glycine (G) residues.  Other homologs to importin β have been identified that interact 
with various nuclear localization sequences directly to facilitate nuclear entry.   
Ran is a guanine-binding protein that serves as an “escort protein” to a cargo-
bound importin complex.  The cargo-bound importin and Ran-GDP complex interacts 
with the FG-nucleoporins in a successive fashion, eventually passing through into the 
nuceloplasm.  Once inside the nucleus, Ran-GTP interacts with the importin complex, 
causing a conformational change that releases the cargo.  Ran-GTP then escorts the 
unbound importin heterodimer back into the cytoplasm46. 
 
Project Purpose 
The goal of this project was to demonstrate entry and nuclear localization of M13 
phage bearing a heptamer peptide into eukaryotic cells in culture.  Visualization was 
achieved using amine-reactive fluorochromes that can be directly conjugated to the abundant 
pVII surface coat proteins of the phages.  Evidence of the peptide’s capability to confer 
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nuclear localization potential to a bacteriophage will justify further examination of the 
peptide and the methods used in the peptide’s discovery. 
Ashley Aston-Weiner’s previous work isolated a sequence that localized to the nuclei 
of both MCF-7 and MCF10A cells.  She used a phage display library (Ph.D.-7, New England 
Biolabs, E8100S) to generate a wide variety of phages displaying different heptamer peptides 
on their pIII coat proteins.  The phages were incubated with MCF-7 and MCF10A cells 
overnight, and then the nuclei of the cells were isolated.  Phages associated with the isolated 
nuclei were recovered, amplified, and sequenced to determine the possible peptide sequences 
that conferred the potential for nuclear localization.  The sequence QPSPSPST was 
frequently displayed by phages rescued from the nuclei of both cell lines.   
In the same project, visualization of phage localization was also attempted using 
immunohistochemistry methods.  The need for antibody entry into the cell—and presumably, 
the nucleus—significantly complicated the permeabilization approach.  Incomplete and/or 
variable permeabilization complicated interpretation of the IHC in assessing the location of 
the phage.  Therefore, in regards to visually verifying the intracellular localization of phage, 
immunohistochemistry is not sufficient.  A different strategy was necessary—one that 
allowed the phage to be labeled prior to incubation with cultured cells.  The detection method 
also required that the label be detectable without permeabilizing the cells.  A literature search 
revealed a novel technique for directly labeling the pVIII coat protein of an M13 
bacteriophage with an amine reactive succinimidyl ester such as the Alexa Fluor line of 
fluorochromes.
 16
Materials and Methods 
 
 
Phage Labeling 
 
As described in Jaye, et al. 200139, phage suspension initially at 4º or -86º C and 
mixed 1:1 with 100% glycerol containing on the order of 1013 plaque forming units 
(determined by titer), was 
added to microfuge tubes 
(Sigma, Z666505) along 
with ¼ volume of sterile 
20% polyethylene glycol-
8000 (Sigma P413) and 
2.5M NaCl (Fisher, S603-
4) precipitation buffer.  The 
mixture was vortexed and 
maintained at 4º C for at 
least four hours before 
centrifuging at 4º C, 20,000 RCF for 20 minutes in a microcentrifuge (Eppendorf, Z2413-R).  
The supernatant was discarded, and 5 μL of 5% w/v Alexa Fluor 647 in dimethyl sulfoxide 
(DMSO) were added to the tubes of phage for labeling.  95 μL of 1 M NaHCO3 conjugation 
buffer were then added to each tube.  Tubes were placed in the dark for one hour, with 
vortexing every 15 minutes.  After the conjugation period, 200 μL of precipitation buffer 
were added to each tube and the tubes were placed at 4º C for at least one hour.  All tubes 
Figure 3: Schematic depicting fluorochrome-labeling process for M13 
bacteriophages. 
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were then centrifuged at 4º C, 20,000 RCF for 15 minutes, and the supernatant was 
discarded.   
200 μL of precipitation buffer was once again added, and the tubes were placed at 4º 
C for at least one hour before centrifugation at the same conditions as before.  This step was 
repeated once more and then the phages were resuspended in 100 μL of a 100 mM NaCl, 10 
mM HEPES, ph 7.9 suspension buffer.  To ensure a lack of free fluorochrome in the final 
labeled phage suspension, supernatants were collected after washings and analyzed using a 
Nanodrop Spectrophotometer (ND-1000, Nanodrop Inc.) calibrated to detect Alexa Fluor 647 
at its optimal excitation and emission wavelengths. 
As a negative control, the above process was performed without the addition of 
fluorochrome and DMSO to the negative control tubes. 
 
Phage Agglomerate Sizing and Filtration 
 
Samples of labeled and unlabeled phages that had gone through the steps of the above 
procedure were diluted to 200 μL (~1013 PFU) in suspension buffer and pipetted into clean 
cuvettes suitable for use in the Zetasizer Nano ZS particle measuring device (Malvern).  
Particle size distributions were assessed using both continuous and discrete modes.  Raw data 
obtained by the Malvern DTS companion software program were exported to tab-delimited 
format for use in Excel and SigmaStat.  Phage agglomerates greater than 5.0 μm in diameter 
were filtered out of suspension using Ultrafree PVDF centrifugal filtration devices 
(Millipore, UFC40SV25).  The filtrate was harvested, its particle size distribution was 
reassessed again, and the remainder was collected for use in the phage incubation and 
staining, as described below. 
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Phage Incubation and Cell Staining 
 
Approximately 103 cells were added to each well of a 12-well plate with 1 mL of 
OptiMEM reduced serum media and allowed to adhere for 8 hours.  Approximately 1010 
plaque forming units of labeled or unlabeled, targeted or untargeted phage were added to the 
appropriate wells.  The plate was placed on a shaker in a 37º C incubator overnight.  The next 
morning, the wells were aspirated and washed thrice with Ca2+, Mg2+ free PBS (CMF-PBS) 
(Sigma, P-4417) and 500 μL of 3.7% paraformaldehyde was added to each well for 30 
minutes.  The wells were washed thrice with CMF-PBS, and 900 μL of 300 nM DAPI in 
Ca2+, Mg2+ free PBS was added to each well for 5-7 minutes.  The wells were once again 
washed thrice with CMF-PBS, 500 μL of fresh CMF-PBS were added to each well, and the 
cells were observed under a fluorescent microscope. 
 
Nuclear Visualization 
 
Cells were observed with a Nikon Eclipse TE2000-U fluorescent microscope with 
Hammamatsu CCD attachment.  Although the camera was capable of color image capture, 
all photos were taken in 8-bit grayscale to make the image files readable on other computers.  
Cell nuclei stained with DAPI were visualized with a Nikon DAPI-FITC-Texas Red triple 
cube filter (Nikon, 96356), while a Cy5 filter (Nikon, 96758) was used to visualize the Alexa 
Fluor-labeled phages.  Typical exposure time for visualizing DAPI stained nuclei was 200 
msec, while exposure time was up to 5 seconds for phage visualization.  Exposure times were 
significantly less for phages labeled with Alexa Fluor 488.  Original captured images were 
stored unmodified in 8-bit grayscale TIFF format in order to be available for later analysis.   
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Image Processing 
 
Due to the limitation of the ImagePro 5.0 software used to take pictures from the 
fluorescent microscope, photographs had to be taken in 8-bit grayscale.  Images were colored 
and combined in Corel PhotoPaint 12, and the processed images were stored in PNG format.   
8-bit grayscale TIFFs created by the ImagePro 5.0 software from triple cube filter 
photographs were converted to blue, while the Cy5 filter photographs were converted to red.  
FITC filter photographs were converted to green.  The Cy5/FITC photographs were placed 
over the DAPI photographs of the same frame, and the black pixels were removed using the 
Color Transparency algorithm.  Remaining pixels were outlined by the program, and circles 
were drawn around red clusters larger than 3 pixels.  These photographs were exported to 
PNG or JPG format, and some were combined with phase contrast photographs using the 
same transparency algorithm.  A 1:1 scale was maintained during each manipulation to 
minimize image processing artifacts.  The original files were also saved in order to ensure the 
integrity of future follow-up analyses. 
 
Details of the experiment used to generate photographs from 9th May and 12th May: 
 
In each of six 1.5 mL microfuge tubes, 200 μL of QPSPSPT-displaying phages 
(approximately 2E13 Plaque Forming Units) were combined with 50 μL of precipitation 
buffer.  Tubes were refrigerated for at least one hour at 4º C and then centrifuged at 20,000 
RPM, 4º C for 15 minutes.  Pellets were resuspended in 200 μL of conjugation buffer, and 
Alexa Fluor 488 was added to each tube in increasing amounts—0.25, 0.5, 0.75, 1.0, 1.5, or 
2.0 μL.  The tubes were incubated for one hour in the dark at room temperature and vortexed 
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every 15 minutes.  50 μL of precipitation buffer were added to each tube, and the tubes were 
maintained at 4º C for at least one hour.  The labeled phages were washed twice with 200 μL 
of precipitation buffer to eliminate free-fluorochrome, and the washed pellets were 
resolubilized in 200 μL of HEPES/NaCl suspension buffer and maintained in the dark at 4º C 
until ready for use. 
MCF-7 and MCF10A cells were subcultured and dispensed into each well of a 
separate 24 well plate with a seeding density of 5000 cells/well.  The cells were allowed to 
attach and grow in serum-containing media (see Appendix A) for 24 hours.  Three of the four 
wells in a column of the 24 well plate received up to 10 μL (approximately 1012 PFU) of 
phages from one of the six tubes of phages labeled in varying concentrations of flurochrome.  
The fourth well received no phages and served as an autofluorescence control to determine if 
any autofluorescence was present.  After addition of phages, the plates were incubated 
overnight (~16 hours) in standard cell culture conditions.   
After the incubation period, each well was washed twice with 500 μL of calcium and 
magnesium-free PBS (CMF-PBS).  500 μL of 3.7% paraformaldehyde were then added to 
each well, and the plates were maintained at 4º C for 20 minutes.  Each well was then washed 
twice with CMF-PBS and the cell nuclei were stained with 300 nM DAPI for ten minutes.  
The wells were then washed twice with CMF-PBS to remove free DAPI.  500 μL of CMF-
PBS were added to each well, and the plates were covered and maintained at 4º C until time 
for viewing. 
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Combined Serum-Free Medium + Transport Mechanism 24-Well Plate Experiments 
 
All wells of a 24-well plate were seeded with 5000 cells of either MCF10A or MCF-7 
cell lines, according to the diagram in Figure 4.  Cells in all wells were allowed to grow in 
300 μL of normal growth medium (containing fetal bovine serum) at standard culture 
conditions for at least 24 hours.  After the growth period, growth medium was aspirated from 
wells in rows marked “SFM” (serum-free medium) in the diagram in Figure 4, and the media 
in these wells was replaced with 300 μL of serum-free medium.  Phages were then added to 
the wells in rows labeled 
“Standard” in microliter 
amounts corresponding to the 
numbers in the circles in 
Figure 4.   
The cells were 
incubated with the phages 
overnight in standard cell culture and conditions.  The next day, cells in all wells were fixed, 
and their nuclei were stained as described in the “Phage Incubation and Cell Staining” 
section.  Cells in the “standard” wells were examined by fluorescence microscopy, and areas 
of interest were photographed.  Then, phages were added to the wells in rows labeled “Pre-
Fixed” in microliter amounts corresponding to the numbers in the circles in Figure 4.  The 
plate was then incubated overnight in standard cell culture conditions.  The next day, the 
wells in the “pre-fixed” rows were washed thrice with CMF-PBS and then received 300 μL 
each of fresh CMF-PBS.  Wells were then examined using fluorescence microscopy. 
 
Figure 4: Schematic of 24-well plate experimental setup.  The 
numbers in each circle denote the volume of labeled phage added to 
each well, in microliters.  1 μL of phage is ~1010PFUs. 
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Phage DNA Extraction and Sequencing 
 
Phage DNA was extracted using the QIAPrep Spin M13 Kit (Qiagen, 27704) as 
directed by the manufacturer.  Briefly, 700 μL (~3 * 1015 PFU) of amplified phage 
suspension were combined with 7 μL of the precipitation buffer provided in the kit and 
loaded into a spin column.  The suspension was vortexed and maintained at room 
temperature for 2 minutes, and then the suspension was centrifuged at 8000 RPM for 15 
seconds.  Filtrate was discarded, and 0.7 mL of phage lysis buffer were added to the spin 
column.  After discarding the filtrate, the column was immediately centrifuged at 8000 RPM 
for 15 seconds, filtrate was discarded, and then 0.7 mL more of phage lysis buffer were 
added to the column.  The column was left in room temperature for 1 minute and then 
centrifuged at 8000 RPM for 15 seconds.   
Filtrate was discarded, and buffer PE (provided in the Qiagen kit) was added to the 
column to remove residual salt from the lysis process, and the column was centrifuged at 
8000 RPM for 15 seconds.  Flow through was discarded, and the spin column was inserted 
into a fresh 1.5 mL collection tube.  100 mL of DNA elution buffer provided in the kit were 
added directly to the spin column membrane, and the spin column was allowed to sit for 10 
minutes at room temperature.  The column was then centrifuged at 8000 RPM for 30 
seconds.  The filtrate was capped and stored at 4º C until sequencing.  The DNA was 
sequenced using the g96III primer included in the New England Biolabs Ph.D.-7 Phage 
Display Peptide Library Kit (New England Biolabs, #E8100S) in the Vanderbilt DNA 
Sequencing Facility. 
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Results 
 
 
 
Nuclear Targeting with Phage 
 
 
Figure 5: Bacteriophages displaying the QPSPSPT peptide labeled with Alexa Fluor 647 (red) are 
localized to the DAPI-stained nuclei of MCF-7 cells (blue) following 18 hours of incubation. 
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Figure 6: Bacteriophages displaying the QPSPSPT peptide labeled with Alexa Fluor 647 (red) are 
localized to the DAPI-stained nuclei of MCF10A cells (blue) following 18 hours of incubation. 
 
 
 
The first fluorochrome chosen was Alexa Fluor 647.  The maximum excitation 
wavelength for this fluorochrome is 647 nm, with a maximum emission wavelength of 
667 nm.  This wavelength is difficult to see with the unaided eye in the fluorescence 
microscope.  Display of this color using the imaging and visualization tools attached to 
the fluorescent microscope is also difficult to resolve by unaided vision.  Thus, another 
fluorochrome was chosen: Alexa Fluor 488, with a maximum excitation wavelength of 
488 nm and maximum emission wavelength of 520 nm, provides a green fluorescence 
compatible with robust visual detection.  Conveniently, with a triple cube fluorescence 
microscope filter, both the excited fluorochrome and DAPI-stained nuclei could be 
identified simultaneously, allowing quick verification of phage localization to cell nuclei.   
 
 25
 
Figure 7: Bacteriophages displaying the QPSPSPT peptide labeled with Alexa Fluor 488 (green) are 
localized to the DAPI-stained nuclei of MCF10A cells (blue) after 18 hours of incubation.   
 
 
 
 
 
Figure 8: Bacteriophages displaying the QPSPSPT peptide labeled with Alexa Fluor 488 (green) are 
localized to the DAPI-stained nuclei of MCF-7 cells (blue) after 18 hours of incubation.  Yellow circles in 
(a) denote faint phage spots. 
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Photographs were obtained that revealed preferential intranuclear and perinuclear 
localization of fluorochrome-labeled phage in MCF-7 and MCF10A cells (Figures 5-8).  
Combining the DAPI and phage filter photographs with phase contrast photos of the cells 
indicated that perinuclear phage localization was within the cell, but did not overlap the 
DAPI-stained nucleus.  Further controls using phage that were fluorescently labeled but 
did not display the nuclear targeting peptide failed to demonstrate intracellular or nuclear 
localization. 
The fields were analyzed, and the total number of phage spots, the total number of 
stained nuclei, the total number of nuclei bearing at least one phage spot, and the number 
of extracellular phage spots were counted.  Based on the data obtained from the fields, it 
was estimated that the QPSPSPT-diplaying phages localized to 12.2% of MCF-7 cell 
nuclei, and to 34.2% of MCF10A cell nuclei.  4.5% and 4.8% of the phage spots were 
located extracellularly in the MCF-7 and MCF10A fields, respectively  
After a thorough search, no areas of interest were noticed in the wells in which 
phages had been added after the cells had been fixed and stained.   
 
 
Phage Labeling 
 
Table 1: Fluorescence readings of free fluorochrome in successive washes after completion of phage 
labeling.  Units are relative and arbitrary. 
Average Phage Wash 1: (88.4 +/- 0.7) * 10 3 
Average Phage Wash 2: (20.0 +/- 1.0) * 103 
Average Phage Wash 3: 280 +/- 5 
Average Control Wash: 20.7 +/- 38.0 
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Residual fluorescence was reduced to approximately the level of fluor-free control 
after three washes.  Unconjugated Alexa Fluor was removed to minimize artifacts from 
cellular uptake of free fluorochrome not associated with phages.   
 
 
DNA Sequencing 
 
Phage DNA was sequenced at the Vanderbilt DNA Sequencing Facility after 
amplification of phages.  By inspection of the data, the portion of the coding strand which 
coded for the heptamer peptide was isolated.  The coding portion of the sequence was 
CAG CCT TCG CCT TCT CCT ACG.  By comparison to a reverse codon table, the 
heptamer peptide Gln-Pro-Ser-Pro-Ser-Pro-Thr (one letter code: QPSPSPT) was 
confirmed.  The complete sequence is shown in Appendix B.  
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Discussion 
Fluorescently labeled M13 bacteriophage displaying the QPSPSPT peptide 
preferentially localized to the nuclei of MCF-7 and MCF10A cells in culture. Nonnuclear 
localization was not observed in fluorescently labeled phages lacking display of the 
heptamer peptide.  Visualization of the intracellular localization of phage expressing the 
heptamer peptide on its pIII coat protein was an important verification step in the process 
of isolating and characterizing a novel nuclear localization sequence.  Fluorescence 
microscopy and subsequent imaging processing provided a precise method of localizing 
two-dimensional phage position in the cell.  Furthermore, phage internalization only 
occurs in live cells and requires an incubation period greater than one hour.  The failure 
of phage to enter fixed cells supports phage cell entry as an active cellular process.   
The frequency of observed nuclear interaction was estimated to be 12.2% and 
34.2% for MCF-7 and MCF10A cells, respectively.  A high frequency of nuclear 
localization is desirable in order for the peptide to be functional in gene therapy.  
However, there is a possible limiting factor based on the detection equipment.  Individual 
phage particles might be difficult to detect using fluorescence microscopy, especially if a 
phage has fewer fluorochrome labels.  It is possible that many of the nuclei only have a 
few labeled phages associated with them, making detection by fluorescence microscopy 
difficult.  Furthermore, quantitative, statistical analysis of phage nuclear localization 
using fluorescence microscopy is difficult because of the thousands of cells in each well.   
There could be more phage-nucleus interaction occurring than fluorescence 
microscopy could detect.  Flow cytometry would be a better solution for future 
quantitative work but would likely require the difficult step of nuclear isolation.  The 
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incubation period could also be varied.  A 16-hour incubation period was standard, but it 
is possible that the results could change if different incubation periods are used. 
 A significant portion of the intracellular phage is observed at the borders of the 
stained nuclei.  A possible explanation for this is that the phage is interacting with the 
nuclear envelope.  Furthermore, aggregates of labeled phage would be less likely to enter 
the nuclei than unaggregated phage.  Isolated, fluorochrome-labeled phage would likely 
be difficult or impossible to see with fluorescence microscopy.  DAPI is an intercalating 
dye; it binds to grooves in double-stranded DNA.  Thus, it is likely that the outer portions 
of the nucleus, which contain the nuclear membrane and pore complexes, are left 
unstained by the dye. 
It is possible that over the incubation interval, many of the phages and their 
attached fluorochromes are destroyed by the cell endosomes.  Perhaps only the 
fluorochromes or their fluorescence properties are affected while the phages remain 
intact.  Another possibility is that some intracellular protein binds to the pIII coat proteins 
or to the QPSPSPT sequence itself.  This could explain the proportion of labeled phages 
detected in the cytoplasm and relatively far from the nuclei of the cells.  This should be 
tested experimentally, and there are multiple ways to do so.  One way would be to 
perform a time-course fluorescence microscopy experiment focusing on a single cell or 
group of cells in the presence of labeled phages.  This would theoretically show phage-
cell interaction, including the lifetime of the labeled phage once inside a eukaryotic cell. 
 Fluorescence imaging of the intracellular localization of an M13 bacteriophage 
displaying the heptamer peptide on its pIII coat protein was an important verification step 
in the process of isolating and characterizing a novel nuclear localization sequence.  
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Fluorescence microscopy and subsequent imaging processing provided a precise method 
of localizing phage position in the cell.  By labeling the phage coat protein pVIII directly 
with an amine-reactive fluorochrome, the complications and uncertainties of 
immunohistochemistry were avoided.   Because fluorochrome-labeled phage retains at 
least some of its function39, time-lapse studies can be performed more easily and with 
better controls than a typical study that requires immunohistochemistry.  Direct 
fluorochrome labeling of phage also incurs a substantial reduction in materials cost in 
comparison to immunohistochemistry.  The wide range of excitation and emission 
wavelengths for amine-reactive fluorochromes allows for many interesting color 
combinations and applications. 
 While nuclear localization of QPSPSPT-bearing phage was observed, the 
variability in measured outcomes could use improvement.  In order for the isolated 
peptide to be ideal for gene therapy, it would need to confer the ability to transfect the 
great majority of malignant cells.  Furthermore, improved consistency of nuclear 
localization would require a lower dose of whatever therapy is associated with the 
peptide, thereby reducing cost, toxicity, and side effects.   
 Fluorochrome-labeling may reduce the ability of phage to penetrate eukaryotic 
cells and localize to the nucleus.  The amine-based reactive chemistry used to conjugate 
Alexa Fluor to the phage has nominally equal affinity for all coat proteins, including the 
five copies of pIII that display the targeting peptide.  An increase in phage diameter or 
interference with the five pIII coat proteins displaying the nuclear localization sequence 
are two ways in which nuclear targeting could be diminished.  There are approximately 
2,700 copies of the pVIII coat protein on the surface of an M13 phage.  The ratio of pIII 
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to pVIII (5:2700) was leveraged with careful selection of the Alexa Fluor concentration 
to minimize fluorescent labeling of the displayed peptide in order to preserve targeting 
function.  The likelihood of many phages having the heptamer peptide fouled by the 
fluorescent label is therefore infinitesimal.  However, the addition of multiple 
fluorochromes onto the phages could increase its hydrodynamic radius, making active 
transport of the phages into eukaryotic cells more difficult. 
An important practical assessment of the QPSPSPT peptide’s ability to localize to 
cell nuclei would involve its incorporation into a non-viral gene therapy construct such as 
a liposome.  Incorporation of polylysine into cationic liposomes has shown to improve 
their efficacy by an order of magnitude7.  Incorporation of the nuclear localization 
sequence from the large T antigen of the SV40 virus has been shown to increase 
transfection by one to three orders of magnitude42.  Bacteriophages do not normally enter 
eukaryotic cells or localize to eukaryotic nuclei, and this inherent characteristic may 
confer a disadvantage to the nuclear targeting ability of the QPSPSPT peptide.  
Bacteriophage display is an effective method for isolating novel peptides.  However, their 
use in gene therapy is minimized by their lack of affinity for eukaryotic cells and their 
ability to cause inflammation.  The QPSPSPT peptide should be tested in non-viral gene 
therapy constructs to evaluate its clinical potential. 
 The interaction of the QPSPSPT peptide with nuclear structures could be studied 
further by incorporating the peptide into alternative reporters such as nonviral gene 
therapy constructs or by ligating the peptide to radioactive or fluorescent markers such as 
quantum dots.  The discovery of future peptides relevant to flexible and therapeutic 
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approaches will likely still rely on biopanning experiments similar to those described by 
Ashley Aston-Weiner and visual confirmation experiments as described here. 
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CHAPTER III 
 
 
 
MANUSCRIPT 2: DETECTION OF MATRILYSIN BY FIVE CANCER  
CELL LINES  
 
 
 
Introduction 
 
 
 
Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a group of 23 enzymes produced by 
human cells.  Their name implies two characteristics.  First, this class of proteins is 
collectively able to break down every known and tested component of the extracellular 
matrix.  Second, these enzymes are regulated by, and are dependent upon, a zinc ion90.  
There is an unpaired cysteine, Cys73, in the cleavable pro-domain of the zymogen form of 
MMPs that binds to a zinc atom.  As 
long as the pro-domain is in place, the 
zymogen is inactive and hydrophobic.  A 
change in conformation or proteolysis 
(either from autolysis or other 
proteinases) results in detachment of the 
thiol group of the cysteine (known as a 
“cysteine switch”) from the zinc ion 
allowing water to hydrolyze the zinc ion, 
and activating the MMP80.  
Figure 9: Matrix metalloproteinases are activated by 
cleavage of the pro-domain, which also makes the enzyme 
water soluble75. 
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MMPs are typically subdivided into six groups.  The first four groups are named 
after their primary substrate, but most MMPs within these groups have other substrates as 
well.  The collagenases include MMPs 1, 8, and 13.  The gelatinases include MMPs 2 and 
9.  The stromelysins include MMPs 3, 10, and 11.  The matrilysins include MMPs 7 and 
26.  The membrane-type MMPs constitute the fifth group, and as the name suggests, they 
are bound to the cell surface.  MMPs 14, 15, 16, 17, 24, and 25 are in this group, and 
their primary substrates are gelatin, fibronectin, and laminin.  The sixth group contains 
the rest of the MMPs: 12, 19, 20, 21, 23, 27, 28.  The substrates of this last group of 
metalloproteinases are either not known or not easily categorized75.   
In healthy humans, the MMPs are highly regulated and serve a variety of tissue 
remodeling functions such as wound healing71, angiogenesis25, involution of the prostate 
after castration89, bone and tooth growth and remodeling90, immune defense9,87, 
reproductive function15, or vascular permeation to allow the passage of immune system 
cells like macrophages16.  The MMPs are regulated at every step from transcription to 
zymogen activation.  The MMPs are essential for life, as evidenced by the early death of 
knockout mice lacking genes for MMPs.  However, the degradation capabilities of the 
MMPs also aid migrating cancer cells during metastasis72.  Thus, MMPs have gained 
status as prognostic indicators of metastasis and as drug targets.  MMPs have a wide 
variety of substrates, and can be both helpful and harmful to healthy tissue3,13.  Their 
propensity to either end takes into account many factors and is therefore not easily 
defined. 
MMPs become a problem when they are not properly physiologically regulated10.  
Along with cancer, abnormalities in MMP regulation can become a factor in various 
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cardiovascular ailments such as myocardial infarction and atherosclerosis, as well as in 
inflammatory disorders such as rheumatoid and osteoarthritis.  Once MMP balance is 
disrupted, the destructive momentum can increase rapidly6.  MMPs can cleave other 
MMPs, thereby increasing the varieties of ECM substrates vulnerable to cleavage.  
Cleavage of the ECM can reveal hidden domains in the matrix proteins that serve as 
growth or migration-promoting factors.  Furthermore, cleavage of cell-surface proteins 
such as E-cadherin, FGF, TGF-β, IGF, TNFα, Fas ligand, and IL-1β can promote cell 
migration and invasion, or prevent the cell from receiving apoptosis signals80. 
Several MMP inhibitors, both specific and broad spectrum, have reached clinical 
trials85,84,66,23.  These trials as a whole were unsuccessful; one MMP inhibitor, tanomastat, 
was found to accelerate the progression of the cancer.  The most common problem with 
these drugs was musculoskeletal side effects.  Based on preclinical evidence, however, it 
could be argued that these trials were not thorough enough to sufficiently evaluate the 
potential of MMP inhibitors.  The trials were based on the “brute force” approach of the 
maximum tolerated dose rather than using escalating dosage patterns.  Furthermore, the 
trials focused on patients in the later stages of cancer.  Another reason for the 
ineffectiveness of these treatments could be surmised from the results of studies in 
knockout mice that show upregulation of other MMP species to compensate for a 
reduction or loss of function of one or a few members of the family90.   
 
Matrilysin 
MMP-7, hereby referred to as matrilysin, is the smallest of the known 
metalloproteinases, along with MMP-2624.  It contains only the domains necessary for 
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secretion and function: a signal peptide, a cleavable pro domain, and a catalytic domain, 
achieving a molecular weight of approximately 28 kDa in its passive form and 19 kDa in 
its active form (sans pro domain).  It lacks a hinge region, as well as fibronectin repeats 
and hemopexin-like domains found in other MMPs.  Its diminutive structure does not 
limit its range of function, as it is a valuable enzyme to healthy and malignant tissue 
alike33.  So far, matrilysin is known to assist in healthy body function by maintaining 
immune function73, wound healing, and degradation of non-essential or exhausted tissue 
(especially during embryonic development).  It is constitutively expressed by a variety of 
exocrine glands, including mammary glands, the liver, the prostate, the pancreas, 
intestinal tissue45, and the peribronchial glands.  Matrilysin also plays a crucial role in 
tumor progression, allowing degradation of ECM components and activation of 
hormones and growth factors, both of which assist tumor proliferation and migration, up 
to and including metastasis14. 
Matrilysin’s methods of assistance to healthy and malignant tissue extend beyond 
the sole function of extracellular matrix degradation.  Injured lung epithelial cells secrete 
matrilysin at their basal surface.  In this case, matrilysin cleaves syndecan-1, which binds 
to a chemokine44.  This creates a chemokine gradient that orients migrating neutrophils.  
Matrilysin is expressed at injury sites in the lung epithelium, and although the reason is 
unknown, matrilysin is necessary for normal wound healing.  Knockout mice lacking the 
matrilysin gene have severe lung wound repair defects; these defects are worse than 
defects caused by the knockout of other MMP genes. 
Matrilysin has been shown to aid in immune function in several ways.  One 
famous way involves the activation of α-defensins in mice, also known as cryptdins -- 
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small antibacterial peptides.  Matrilysin cleaves the precursor form of the cryptdin, 
activating it and allowing the peptide to puncture bacterial membranes.  In normal mice, 
matrilysin expression parallels cryptdin expression.  In knockout mice lacking the gene 
for matrilysin, no cleavage of the procryptdin occurs and the ability to battle enteric 
pathogens is substantially inhibited9.  Matrilysin also assists with macrophage invasion.  
Macrophages produce matrilysin, which helps them degrade and extravasate through the 
extracellular matrix.  Another study shows that matrilysin is required for herniated disc 
resorption by macrophages.  In this scenario, the presence of matrilysin was also required 
for the secretion of TNF-α, an inflammatory mediator31.   
However, matrilysin is also of tremendous help to growing and metastasizing 
tumors, as evidenced by its expression in tumors of every organ type.  In fact, the 
presence of matrilysin mRNA is shown to increase with the stage of cancer and during 
dysplasia and metastasis47.  When it comes to cancer, an increase in matrilysin worsens 
the prognosis41.  While many studies focus on the negative influence of matrilysin on 
cancer survival, there is also new evidence of a correlation between the presence of 
matrilysin and favorable prognostic markers.   
Matrilysin is known to be important in regulating cell-surface proteolysis.  It can 
bind E-cadherin, β-catenin, Fas ligand, TNF-α, and heparin sulfate47,59.  A recent paper 
by Nakamura et al details the cleavage of the entire six-variant spectrum of Insulin-like 
Growth Factor Binding Proteins (IGFBP) by matrilysin.  IGFBP is a modulator of 
Insulin-like Growth Factor (IGF) availability, and thus this action liberates IGF, which 
can then help a growing tumor acclimate to its surroundings60.   
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Another negative role of matrilysin is its involvement in atherosclerosis in 
humans.  Matrilysin, along with several other MMPs, is secreted by lipid-laden 
macrophages buried behind the fibrotic tissue of a vessel wall lesion.  The finding that 
matrilysin has two major substrates in an atherosclerotic lesion, versican and tissue factor 
protease inhibitor, suggests the role of matrilysin in both plaque destabilization and 
downstream thrombosis formation62.   
Clinical trials involving inhibitors of matrilysin have proven unsuccessful.  
However, much has been learned about these enzymes in the course of developing 
inhibitors for them.  Cleavage sequences for some MMPs are now known, and they will 
likely prove valuable for the newest class of targeted nanoscale imaging and therapeutic 
solutions.  These constructs involve the use of fluorescent functionalized nanoparticles 
such as quantum dots and an attached peptide linker which can be proteolytically cleaved 
to allow drug interaction or fluorescence.   
To date, no published study has attempted to quantify the amount of matrilysin 
produced by cancer cells using proteomic analysis.  mRNA analysis has been attempted 
using RT-PCR, but this is an indirect, non-quantitative measure of actual protein 
production, as the mRNA transcripts can be degraded before translation.  Furthermore, a 
single mRNA can be translated multiple times before it is degraded.  A more accurate 
way to measure matrilysin would be the through the use of an ELISA using antibodies 
specific for matrilysin, which measures the amount of protein present, or by using an 
activity assay, from which the concentration of matrilysin in a supernatant sample could 
be calculated.     
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Cathepsin D 
Cathepsin D is an aspartic protease that is overexpressed and hypersecreted by 
epithelial breast cancer cells28.  Like matrilysin, elevated levels of cathepsin D are 
associated with poor prognosis, as the enzyme is known to stimulate tumorigenicity and 
metastasis.  Cathepsin D modified by mutation to be enzymatically inactive can still 
function as a mitogen.  This suggests that cells possess a receptor specific for cathepsin 
D, although one has yet to be located.  Other paracrine actions of cathepsin D are the 
stimulation of angiogenesis, remodeling of the extracellular matrix, decreased apoptosis, 
and increased motility.  There is also evidence that cathepsin D in its zymogen form 
serves as a promoter of fibroblast outgrowth56.  Cathepsin D has no known endogenous 
inhibitor, but expression is thought to be highly regulated by estrogen28. 
 
Cancer cell lines 
MCF-7 cells are a well-known and well-characterized epithelial breast cancer cell 
line82.  In normal culture, they produce small amounts of matrilysin82.  However, MCF-7 
cells have also been shown to increase their production of matrilysin when exposed to 
certain hormones in culture such as relaxin and epidermal growth factor14.  This is 
important because in a physiological setting, oncogenic upregulation of particular factors 
could change the production level of matrilysin. 
MCF10A is an immortalized, non-tumorigenic cell line isolated from benign 
breast fibromas.  Like normal breast cells, the MCF10A cell line forms three 
dimensional, dome-like acinar structures in collagen, its growth can be controlled by 
exogenous growth factors, and adhesion is required in order to proliferate76.   
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SW480 and SW620 cells are isolated from malignant epithelial colon tumors.  
SW480 cells are not known to produce matrilysin in culture.  SW480NEO cells possess 
an insert that confers resistance to neomycin.  SW480MAT cells possess the ampicillin 
resistance insert but also possess an insert for enhanced production of matrilysin.  SW620 
cells have shown the ability to produce matrilysin in culture95.   
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Materials and Methods 
 
 
 
Western blotting – sample preparation 
Cultures of SW480NEO, SW480MAT, and SW620 colon cancer cell lines were 
obtained from Oliver McIntyre (Vanderbilt University, Department of Cancer Biology). 
Vials of frozen MCF10A and MCF-7 were obtained from American Type Culture 
Collection (CRL10317 and HTB-22, respectively). All cell lines were grown in T-75 
flasks to 70% confluency. At this point the supernatant was removed and replaced with 
serum free media. After 48 hours the supernatant from each flask was removed and 
centrifuged through an Amicon Ultra 10 kDa molecular weight cutoff filter (Millipore, 
UFC900508) and the residual fluid was recovered. Recombinant human matrilysin and 
MMP-13 obtained from R & D Systems (WBC016, WBC030, respectively) as well as 
concentrated matrilysin provided by Dr. Michael van Saun of the Lynn Matrisian lab 
(Vanderbilt University, Department of Cancer Biology) were used as positive controls. 
DMEM with 10% FBS (Atlanta Biologicals, S11150) was used as a negative control.  
 
Western blotting – gel electrophoresis 
The samples were then loaded into a 10% Tris-Tricine gel (Life Therapeutics, 
NT11-010), and the gels were electrophoresed at 150 V for one hour in a Bio-Rad Mini-
Protean II electrophoresis chamber (165-2960).  A coomassie blue assay was performed 
in a separate electrophoresis run to verify correct technique before attempting the 
Western blot. Electrophoresed gels were blotted to an Immobilon-P
SQ 
PVDF membrane 
(Millipore, ISEQ10100) designed to more efficiently retain small proteins. Total protein 
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stain on the blot was performed using SYPRO Ruby fluorescent stain (Molecular Probes, 
S-12001) to verify successful blotting. Blocking of the membrane was performed with 
2.5% Carnation Dry Milk and 0.05% TWEEN-20 (Sigma, P-5927) in standard Tris 
Buffered Saline (TBS) (Sigma, T3203). After three 15 minute washings in TBS, primary 
antibody incubation was performed at a dilution of 1:104 overnight on a platform shaker 
at 4° C. After three 15 minute washings in TBS, the blot was incubated with secondary 
fluorescent-conjugated antibody at a dilution of 1:104 for one hour at room temperature.  
 
Western blotting - detection 
The imaging strategy involved the use of secondary anti-mouse antibodies 
(Molecular Probes, A-21093) conjugated to Alexa Fluor 350 fluorophores to bind to the 
primary antibodies (Murine anti-MMP-13 and anti MMP-7, EMD Biosciences, IM71T 
and IM78T) on the blot. Blots were then imaged in a BioDocIt gel box (UVP, 
Cambridge, MA). To verify feasibility, 5 μL of secondary antibody suspension was 
pipetted onto a small piece of blotting membrane, and the membrane was placed in the 
gel box with the UV light source set to 350 nm. The antibody suspension exhibited strong 
fluorescence and was easily imaged by the gel box camera.  
 
Immunoprecipitation 
Immunoprecipitations were performed using the Sigma Protein G 
Immunoprecipitation Kit (IP-40, Sigma, Inc.).  200 μL of supernatant from each of the 
cell culture samples incubated in serum-free medium were transferred to the included 
microcentrifuge spin columns.  2.5 μg of purified monoclonal antibodies to the protein of 
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interest (matrilysin or cathepsin D) were also added to the spin columns, along with 400 
μL of the included immunoprecipitation buffer.  The spin columns were capped and 
placed on a rotisserie mixer for at least 4 hours at 4º C.  In the meantime, 30 μL per spin 
column of the protein G agarose beads included in the kit were washed twice with 1 mL 
of cold immunoprecipitation buffer and resuspended in 50 μL of immunoprecipitation 
buffer.  After the incubation, the washed protein G beads were transferred to the spin 
columns, and the columns were incubated at 4º C for at least 4 hours on a rotisserie 
mixer.   
After the incubation, the columns were centrifuged to remove unbound protein 
and antibodies.  The spin columns were then washed by adding immunoprecipitation 
buffer and centrifuging five times.  One additional wash was then performed with low-
strength (0.1X) immunoprecipitation buffer.  40 μL of Tris-Tricine-SDS Sample Buffer 
(Gradipore, BG-125) were added to each of the columns, and the columns were 
immersed in boiling water for five minutes.  The spin columns were then centrifuged to 
collect eluted proteins, and the effluent from each column was loaded onto a 10% Tris-
Tricine gel.  The gel was electrophoresed at 150 V for one hour, and the gels were stained 
with coomassie blue (ICN, 190343) overnight and destained with a solution of 10% 
methanol (Fisher Scientific, TIA947-4)  and 7% acetic acid (Fisher Scientific, A35-500) 
until an acceptable amount of the coomassie stain was removed. 
 
MMP assay – cell kinetics measurement 
Cell lines were maintained in T-75 flasks (Falcon, 353136) under standard culture 
conditions.  MCF-7 and MCF10A lines had specific media formulations, while the sw480 
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and SW620 colon carcinoma lines used a common media (see Appendix A).  Eight six 
well plates, one for each time point, were seeded with approximately 105 cells per well 
based on a cells/mL count obtained from a Beckman-Coulter Multisizer 3 particle 
counter.  Each cell line occupied one well in each of the six-well plates, and appropriate 
growth media was added up to 2 mL per well.  At each time point, 200 μL of supernatant 
from each well were placed in microfuge tubes and stored at -70° C.  The rest of the 
media was aspirated from each well and replaced with 1 mL of 1X Trypsin-EDTA 
solution (Gibco 25200-056).  Cells/mL counts were then obtained using a Beckman-
Coulter Multisizer 3 Particle Counter. 
 
MMP activity assay  
A fluorescence-based enzymatic activity assay (Enzolyte 520 Assay kits, 
Anaspec, 71150 and 71153) was performed to determine the presence and concentration 
of matrilysin.  50 μL of cleavable substrate specific for matrilysin were added to each 
well of a 96 well plate (Sigma, N1142), and 50 μL of supernatant mixed with 1 mM 
APMA (included in the kit) were put into the appropriate well.  The plate was incubated 
for 30 minutes at room 
temperature before the 
fluorescence readings 
were recorded.  The 
MCF-7, SW480MAT, 
Figure 10: Fluorescent substrate assays were performed on a 96-well 
plate according to the setup shown. 
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and SW620 cell lines had two sets of columns, while SW480NEO and MCF10A only had 
one column apiece due to substrate limitations (Figure 10).  Controls included assay 
buffer only, water only, and media only.  All assays mentioned in this paper were 
performed in black 96-well plates (Sigma CLS3991) using a Bio-Tek Synergy HT Plate 
Reader. 
 
MMP assay – antibody-based ELISA 
An ELISA based on antibodies to the zymogen form of MMP-7 (Amersham 
Biosciences, RPN2620) was performed using the supernatants from MCF-7 and 
MCF10A cell lines.  Standard wells were set up on the same plate in parallel with the 
sample wells according to the kit instructions.  100 μL of cell culture supernatant were 
pipetted into the appropriate wells, 10 μL of 20mM EDTA were added to each well, and 
the plate was incubated in the dark at 4° C for 16 hours.  All wells were then washed with 
the wash buffer included in the kit.  After washing, 100 μL of peroxidase conjugate were 
pipetted into each well and the plate was incubated in the dark at 4° C for 1 hour.  All 
wells were then washed four times with wash buffer and 100 μL of TMB substrate were 
immediately added to each well.  The plate was then stored at room temperature in the 
dark for 30 minutes.  100 μL of 1 M sulfuric acid were then added to all wells to stop the 
reaction.  The plate was read in a Bio-Tek Synergy HT Plate Reader at 450 nm.   
 
Substrate tests 
The same substrate used in the Enzolyte MMP-7 assay kit was purchased 
separately from Anaspec (catalog #60574-01).  Substrate arrived desiccated in 0.1 mg 
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aliquots.  When ready for use, the substrate was solubilized in 60 μL of dimethyl 
sulfoxide (DMSO).  Solubilized substrate was further diluted 1:100 with assay buffer 
provided in the Enzolyte kit.  Substrates were incubated with cell culture supernatant, 
with some samples supplemented with 10 μL of Roche Complete Protease Inhibitor (mini 
tablets dissolved according to manufacturer’s instructions) (Roche, 11836170001) and/or 
10 μL of 0.2 M EDTA (Fisher, C-3920), pH 9.0. 
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Results 
 
 
 
Western blot detection of matrilysin synthesis 
 
 
 
Figure 11:  Western blot using infrared-absorbing secondary antibodies. Blue circle denotes signal from 
SW480MAT lane, violet circle denotes faint SW620 signal, black circle denotes positive control.  Lanes 
from left to right:  1--MCF-7, 2--MCF10A, 3--SW480NEO, 4--SW480MAT, 5--SW620, 6--ladder, 7--
MMP-7enzyme control, 8--MMP-13 enzyme control. 
 
 
 
A Western blot for matrilysin production produced a positive result for 
SW480MAT cells and a possible positive result for SW620 cells.  The band 
corresponding to SW620 was not as pronounced as the SW480MAT and control bands. 
(Figure 11).  No bands consistent with matrilysin production were detected under the 
same conditions for MCF-7, MCF10A, or SW480NEO. 
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Fluorogenic substrate detection of matrilysin synthesis 
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Figure 12:  Matrilysin synthesis assessed by cleavage of a specific fluorogenic assay.  Fluorescence 
readings vary, but only slightly, based on the addition of protease inhibitor and EDTA.  Supernatant for 
MCF-7 cell culture was most effective in fluorogenic substrate cleavage.   Cell supernatants with positive 
Western blot results have the weakest capacity for substrate cleavage.  The dotted line represents average 
background fluorescence.  MCF-7, MCF10A, and SW480MAT cell line statistics for uninhibited substrate 
cleavage are based on 4 repeats.  SW620 and SW480NEO cell line statistics for uninhibited substrate 
cleavage are based on 2 repeats.  Protease inhibitor and EDTA statistics for all cell lines are based on 3 
repeats.   
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Figure 13: Matrilysin substrate cleavage by purified, active-form matrilysin.  The numbers above the data 
points indicate concentration of matrilysin, in nanomolar units.  Only one set of data was obtained in order 
to verify enzyme and substrate function.     
 
  
 Fluorogenic substrate cleavage was not consistent with the Western blot results.  
Supernatants from MCF-7 cells produced significantly greater cleavage of the 
fluorogenic substrate than the SW40MAT and SW620 cell supernatants, which were 
detected as positive for matrilysin by Western blot (Figures 11, 12).  Supernatant from 
cells in culture for 48 hours was added to the substrate.  Substrate cleavage is slightly 
reduced by addition of broad-spectrum protease inhibitor and EDTA to inhibit 
metalloproteinases.  However, neither of the inhibitors, alone or together, can fully inhibit 
non-specific substrate cleavage.  EDTA inhibited cleavage of the substrate by purified 
matrilysin, as indicated by a reading of 14 +/- 1 units, a reading only slightly above the 
background fluorescence level of 8 +/- 2 units (Figure12). 
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 A one-way ANOVA was performed on the data to determine if a significant 
difference was present amongst the fluorescence intensity measurements.  Analysis of 
measurements from wells without protease inhibitors gave a P value of less than .001, 
indicating a significant difference amongst the fluorescence intensity readings for each 
cell line.  ANOVA analysis was also performed to determine if differences were 
significant amongst the fluorescence intensity readings for the inhibited and uninhibited 
substrate cleavage for each cell line.  The results indicated that significant differences in 
cleavage were present amongst the readings for MCF-7 (P = 0.003), but not MCF10A, 
SW480NEO, SW480MAT, or SW620. 
 
Fluorogenic substrate detection of MMP-13 synthesis   
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Figure 14: Results of an assay for MMP-13 in the supernatants of five cell lines.  The supernatants failed 
to cleave a fluorogenic substrate specific for MMP-13.  Substrate in assay buffer with no supernatant added 
is shown as the control.  Bar height is mean plus standard deviation.  n=8 for each cell line.    
 
 51
 Figure 14 shows that none of the cell supernatants gave fluorescence readings 
above the background level of 10.  Therefore, the data indicate that none of the cell lines 
produced detectable levels of MMP-13.  Water, assay buffer, and empty wells all gave 
readings of zero.  250 nM MMP-13 enzyme added to the substrate as a positive control 
gave readings of 213 +/- 5 units.  A one-way ANOVA test was performed to test for a 
statistically significant difference amongst the data.  The test returned a P value of 0.468, 
indicating that no significant difference was present. 
 
Immunoprecipitation detection of cathepsin D 
 
 
Figure 15: Immunoprecipitation performed on supernatants of seven cell lines gives light bands 
corresponding to the predicted molecular weight of reduced cathepsin D in three of the lanes (aqua oval).  
The lanes are numbered as follows: 1 – MCF-7, 2 – MCF10A, 3 – SW480MAT, 4 – SW480NEO, 5 – 
SW620, 6 – molecular weight ladder, 7 – corneal epithelial cells, 8- dermal fibroblasts, 9 – cell culture 
media only.  The red circle denotes the ladder band corresponding to 56 KDa; the blue circle denotes the 
ladder band corresponding to 101 KDa.  Expected molecular weight of reduced cathepsin D is ~65KDa.  
The image is representative of four repeats. 
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 Immunoprecipitation performed on supernatants from the five cancer cell lines as 
well as supernatants from corneal epithelial cells (ATCC Catalog #CRL-11135) and 
dermal fibroblasts (ATCC Catalog #CRL-1554) kindly provided by the Rick Haselton lab 
(Vanderbilt University, Department of Biomedical Engineering) revealed faint bands 
corresponding to the predicted molecular weight of reduced cathepsin D in the lanes 
corresponding to SW480MAT, SW480NEO, and SW620.  Bands appeared in every lane 
in a region approximately in line with the 56 KDa marker, and were likely antibody 
fragments (Figure 15). 
 
ELISA detection of matrilysin synthesis as a function of time in culture 
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Figure 16:  ELISA for detection of matrilysin zymogen by MCF-7 and MCF10A cell lines is consistently 
negative over a 96-hour interval.  Data points indicate mean + standard deviation.  n=2 
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 None of the time points in Figure 16 gives a signal significantly stronger than that 
of the control.  The detection threshold of the assay corresponded to a signal intensity of 
0.07 ± 0.01, equivalent to a concentration of 5.07 pM or (97 pg/mL, given in the 
accompanying product literature).  A one-way ANOVA was performed on the data to 
determine if the signals from either cell line were significantly different from that of the 
control signals.  For MCF-7, the P value was 0.848, and for MCF10A the P value was 
0.711.  Both values indicate that no significant difference was present in the data. 
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Discussion 
 
Table 2: Summary of proteolytic enzyme synthesis results as a function of cell line and detection 
approach obtained using the detection methods employed in this study.  +++,++, and + indicate strong, 
moderate, and weak positive results, respectively.  – denotes a negative result.  “nd” indicates that 
results were not obtained. 
 MCF-7 MCF10A SW480NEO SW480MAT SW620 
Western blot: MMP-7 - - - +++ + 
Activity assay: MMP-7 +++ ++ + + + 
Activity assay: MMP-7 + 
protease inhibitor +++ + +/- +/- + 
Activity assay: MMP-7 + 
protease inhibitor + EDTA +++ + +/- +/- + 
ELISA: MMP-7 - - nd nd nd 
Western blot: MMP-13 - - - - - 
Activity assay: MMP-13 - - - - - 
 
  
 Western blotting confirmed the presence of matrilysin in SW480MAT and 
SW620 cell cultures, in agreement with other studies95.  Western blotting did not detect 
matrilysin production by MCF-7, MCF10A, or SW480neo cell lines.  However, a 
fluorogenic assay was performed to confirm the Western blots and to estimate the 
production rate of matrilysin by the cell lines over a 96-hour time course.  The 
commercially availably intensity assay uses a fluorogenic substrate uniquely cleavable by 
matrilysin, although some cross-reactivity with MMP-13 is reported by the manufacturer. 
Fluorescence intensity is proportional to the amount of matrilysin activity in the sample, 
enabling a quantitative result.   
 A similar commercial assay, specific for MMP-13, was used to assess the 
potential for matrilysin substrate cleavage by the presence of MMP-13.  None of the cell 
lines produced detectable levels of MMP-13 (Figure 14) and MMP-13 was presumed to 
be absent in the fluorogenic substrate assessment. 
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 The results of the fluorogenic matrilysin assay were not consistent with the 
Western blot results in this study or the other reports in the literature.  Matrilysin 
synthesis by SW480MAT and SW620 cells detected by Western blotting was not 
confirmed by cleavage of the matrilysin-specific fluorogenic substrate.  Of equal 
significance was the matrilysin substrate cleavage observed in MCF-7 (and, to a lesser 
extent MCF10A and SW480NEO) cells without confirmation by Western blotting or 
literature reports.  Fluorescent substrate cleavage by a non-matrilysin, non-MMP-13 
enzyme is one hypothesis consistent with the observed results.   
Experiments designed to test this hypothesis were conducted with cell culture 
supernatants supplemented with broad-spectrum protease inhibitors and/or EDTA, a 
metalloproteinase inhibitor.   The results of these experiments were consistent with 
cleavage of the matrilysin assay substrate by a mechanism other than matrilysin or other 
MMPs.  Fluorescent signal in the presence of strong, multifunctional protease inhibitors 
is consistent with substrate cleavage by mechanisms other than matrilysin or other 
metalloproteinases (Figure 12).  The use of this fluorogenic substrate or a matrilysin 
detection method in complex systems such as cell culture supernatants must be 
approached with caution. 
 Chelation of divalent cations by EDTA supplementation, a necessary cofactor for 
MMP activity, did not significantly reduce substrate cleavage mediated by cell culture 
supernatants.  Combined with undetectable substrate cleavage induced by cell culture 
medium alone, this result suggests that a cell-derived product other than a divalent cation-
sensitive protease is capable of cleaving this substrate.   
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 The addition of a protease inhibitor mixture failed to prevent substrate cleavage 
by cell culture supernatants.  Since this result alone could not exclude MMP activity as 
responsible for substrate cleavage, a set of experiments was conducted using cell culture 
supernatants supplemented with both EDTA and protease inhibitor.  This broad inhibition 
strategy retained the capacity for fluorogenic substrate cleavage.  Tests with culture 
supernatant, protease inhibitor, and the fluorogenic substrate indicated that cleavage of 
the substrate by cell supernatants was only slightly reduced in the presence of protease 
inhibitor, and the results were all above the background readings for every cell line 
(Figure 12).   
The commercially obtained protease inhibitor is not effective against aspartic 
proteases or metalloproteinases.  The potential for a cell-derived aspartic protease to be 
present in the supernatant, uninhibited by EDTA plus the commercial protease inhibitor 
product, and capable of fluorogenic substrate cleavage remained a candidate hypothesis 
consistent with the experimental results.  Cathepsin D is an aspartic protease that is 
known to be upregulated in some cancers.  However, immunoprecipitation using 
antibodies to cathepsin D and concentrated supernatant samples from the five cell lines 
failed to reliably detect cathepsin D (Figure 16).  The mechanism of nonspecific substrate 
cleavage remains unknown.   
Future work could be performed to determine what is causing nonspecific 
cleavage of the matrilysin substrate, but these data indicate that quantitative 
determination of matrilysin by a fluorogenic substrate in complex cell culture supernatant 
is not currently possible.  Future work with the cell lines could study the kinetics of their 
progression through an artificial matrix such as Matrigel in comparison to cell lines not 
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isolated from tumors.  Selective addition of active proteases known to be produced by 
MCF-7 and MCF10A cell lines to non-migrating cell lines in the presence of Matrigel 
could also help to identify the proteases specifically responsible for cleavage of substrate 
motifs mimicking those present in extracellular matrix.  Protease inhibitors have been 
studied as possible anticancer therapeutic agents.  Furthermore, precise knowledge of 
upregulated proteases could lead to more specific and possibly more effective inhibitors 
of cancer cell migration. 
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APPENDIX A: Cell Media Recipes 
 
MCF-7 media 
50 ml FBS 
5 ml Non-essential amino acids (purchased as a solution) 
5 ml sodium pyruvate (purchased as a solution) 
0.5 ml insulin (purchased as a solution) 
5 ml antibiotic-antimycotic 
435 ml MEM 
 
MCF10A media 
 
25 ml FBS 
10 μl EGF (this is reconstituted at the suggested concentration) 
50 μl cholera toxin (this is reconstituted at the suggested concentration) 
0.5 ml insulin (purchased as a solution) 
1.4 ml hydrocortisone (purchased as a solution) 
5 ml antibiotic-antimycotic 
468 ml DMEM-F12 
 
Sw620 media 
 
50 mL FBS 
450 mL DMEM (high glucose, L-glutamine, with pyridoxine HCl, without sodium 
pyruvate) 
 
Sw480neo/mat media 
 
Same as SW620 except add 5 mL of neomycin and remove 5 mL of DMEM 
 
 
 
Ordering Information: 
 
Calbiochem: 
Cholera Toxin - 227036 
 
Invitrogen: 
MEM - 11095-080 
DMEM/F12 - 11330-032 
Antibiotic-antimycotic - 15240-062  
EGF – 13247051  
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Sigma: 
Insulin Solution - I0516 
Hydrocortisone - H6909 
Sodium Pyruvate Solution (100 ml) - S8636 
MEM Non-essential Amino Acid Solution (100 ml) - M7145 
 
Atlanta Biologicals: 
Defined Fetal Bovine Serum – S11150 
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APPENDIX B: Phage DNA Sequence 
 
 
 
NNNNNNNGNCGNNTTCNGACGTTAGTAATGAATTTTCTGTATGGGATTTTGCTAAACAACTTTCAACAGTTT
CGGCCGAACCTCCACCCGTAGGAGAAGGCGAAGGCTGAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTG
CGAATAATAATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATTGTATCGGTT
TATCAGCTTGCTTTCGAGGTGAATTTCTTAAACAGCTTGATACCGATAGTTGCGCCGACAATGACAACAACC
ATCGCCCACGCATAACCGATATATTCGGTCGCTGAGGCTTGCAGGGAGTTAAAGGCCGCTTTTGCGGGATCG
TCACCCTCAGCAGCGAAAGACAGCATCGGAACGAGGGTAGCAACGGCTACAGAGGCTTTGAGGACTAAAGAC
TTTTTCATGAGGAAGTTTCCATTAAACGGGTAAAATACGTAATGCCACTACGAAGGCACCAACCTAAAACGA
AAGAGGCAAAAGAATACACTAAAACACTCATCTTTGACCCCCAGCGATTATACCAAGCGCGAAACAAAGTAC
AACGGAGATTTGTATCATCGCCTGATAAATTGTGTCGAAATCCGCGACCTGCTCCATGTTACTTAGCCGGAA
CGAGGCGCANACNGTCAATCATAAGGGAACCGAACTGACCAACTTTGAAAGANGACANATGAACGGTGTACA
GACCAGGCGCATANGCTGGCTGACCTTCATCAAGAGTAATCTTGACAAGAACCGGATATTCATTACCCAAAT
CNACGTAANAAAGCTGCTCATTNAGTGAATAAGGCTTGNCCTGANGAGAAACACCAGAACGAGTNGTAAATT
GGGNTTGAGATGTTTNATTTCAACTTTNANNNTTGTGAATTACCTTATGNGATTTTAANNAANTGNCTCATT
NTACNAGTNAGGACGTGGGGAAGAAAANTCTANGTTAANNAAACNANCTAANNNGAANNACANT 
 
The shaded portion of the above sequence is complementary to the following coding 
sequence: CAG CCT TCG CCT TCT CCT ACG.  These codons correspond to the amino 
acid sequence Glu-Pro-Ser-Pro-Ser-Pro-Thr. 
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APPENDIX C: Kinetics Work 
 
 
 
 The results of this study were intended to be used for calibration of a proposed 
targeted therapeutic construct.  The proposed construct consists of a quantum dot 
conjugated to polyethylene glycol chains with incorporated cleavable peptide linkers.  
The polyethylene glycol chains conceal a cytotoxic drug.  In the presence of matrilysin, 
the peptide linkers would be cleaved, exposing the cytotoxic drug to nearby cells.  Since 
breast tumors are known to produce matrilysin in high amounts, the conjugated drug 
would theoretically be preferentially activated in the vicinity of tumors.  The results of 
the study were to assist in calibrating the amount of polyethylene glycol and the amount 
of drug to conjugate to each quantum dot.  Quantitation of matrilysin production has not 
yet been achieved, but this work evaluated two straightforward approaches and explored 
several possible reasons for their conflicting results. 
 Had the results of the activity assay been reliable, they could have been used to 
calculate matrilysin production per cell in each cell line, using the following equation: 
 
Where M is the molarity to reading ratio, calculated from the peak fluorescence reading 
of a calibration assay, Γ is the moles to grams conversion constant based on the 
molecular weight of matrilysin, B is the average background reading from the plate 
reader, ρ is the well’s fluorescence reading, and σ is the cell count at the time point 
corresponding to the well. 
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Figure C.1: Fluorescence intensity readings for the matrilysin activity of five tumor cell lines over a 96-
hour interval, based on cleavage of a fluorescent substrate designed to be specific for matrilysin. 
  
  
 Fluorescence intensity, an indicator of matrilysin activity, was assessed in five 
cell lines from 18 to 96 hours after subculture.  After subtraction of control fluorescence 
based on uncleaved substrate, MCF-7 retained a fluorescence activity of approximately 
500 units, MCF10A stayed around 150 units, and SW480NEO, SW480MAT, and SW620 
cell lines all stayed around 50 units (Figure C.1).   
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Figure C.2:  Representative semi-log growth plot for five cell lines over a 96-hour interval. 
 
  
 At the time of supernatant collection, the cells were detached from the surface of 
the wells and counted.  The cell count data were matched with the fluorescence reading 
for the corresponding time point to give the data for estimated matrilysin production per 
cell, as shown in Table C.1 below. 
 
Table C.1: Estimated levels of matrilysin per cell at each time point, in picograms, based on 
fluorescence readings shown in Figure C.1 
16 119 ± 9 25 ± 3 9 ± 1 10 ± 2 3.9 ± 0.7 Color Key 
25 190 ± 7 21 ± 3 6.1 ± 0.9 8 ± 2 2.3 ± 0.5 MCF-7 
40 177 ± 7 16 ± 2 2.5 ± 0.3 3.3 ± 0.5 0.7 ± 0.1 MCF10A 
48 157 ± 12 14 ± 2 2.1 ± 0.3 2.2 ± 0.3 0.65 ± 0.09 SW480NEO
64 117 ± 8 13 ± 1 0.75 ± 0.1 1.3 ± 0.2 0.28 ± 0.06 SW480MAT 
72 36 ± 2 8.8 ± 0.7 0.77 ± 0.09 1.1 ± 0.2 0.20 ± 0.02 SW620 
88 30 ± .2 4.9 ± 0.4 0.38 ± 0.05 0.7 ± 0.1 0.13 ± 0.02  T
im
e 
(h
ou
rs
) 
96 37 ± .5 6.4 ± 0.6 0.21 ± 0.03 0.7 ± 0.1 0.15 ± 0.01  
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 While the goal of establishing a kinetic, quantitative pattern of matrilysin 
production by cancer cell lines has not yet been achieved, the work above provides one 
way in which it could be estimated once reliable data have been obtained. 
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